NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use.  Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.

The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 will support a project with specific milestones to be accomplished at the end of the 2-year period. The UH3 will provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases.

Through this FOA, NIDA seeks to attract exceptionally talented investigators to the mission of expanding the number and breadth of lead molecules in the pipeline for drug addiction treatment, optimizing these leads, and/or advancing them to clinical testing.

   

Deadlines:

  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): July 25, 2018; July 25, 2019, July 25, 2020
  • AIDS Application Due Date(s): September 7, 2018; September 7, 2019, September 7, 2020

RFA-DA-18-020 Expiration Date September 8, 2020

Agency Website

Amount

$5,000,000

Amount Description

Application budgets are limited to $1,000,000 direct costs per year and need to reflect the actual needs of the proposed project.  

The project period is limited to 2 years for the UG3 phase and 3 years for the UH3 phase.    

Funding Type

Grant

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

July 25, 2019